NCT03025477

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Randomized Study Assessing Two Strategies of First Line: a Strategy With Intraperitoneal Chemotherapy and a Strategy With Total Intravenous Strategy, in Patients With Epithelial Advanced Ovarian Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: Groupe Hospitalier Diaconesses Croix Saint-Simon · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.

Detailed description

This is a randomized phase II study, open-label and multicentric. After initial intervention (debulking surgery or diagnostic surgery) patient will randomized in the study according to Completeness of cytoreduction (CC) score (CC0 or CC\>1).

Conditions

• Ovarian Cancer, Epithelial

Interventions

Type	Name	Description
DRUG	CC0 - Carboplatin (IV) - Paclitaxel (IV)	(6 cycles)
DRUG	CC0 - Cisplatin (IP) - Epirubicin (IV)	(6 cycles)
DRUG	CC>0 - Carboplatin (IV)- Paclitaxel (IV)	* carboplatin (IV) - paclitaxel (IV) (3 cycles) * Interval surgery * Carboplatin (IV) - paclitaxel (IV) (3 cycles)
DRUG	CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)	* Cisplatin (IV) - Epirubicin (IV) (3 cycles) * Interval surgery : * if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles) * if CC\>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)

Timeline

• Start date: 2016-10-01
• Primary completion: 2021-10-01
• Completion: 2032-10-01
• First posted: 2017-01-19
• Last updated: 2021-02-11

Locations

7 sites across 1 country: France